Moderna, Inc. Hits New 52-Week High at $67.74, Signaling Recovery

Moderna, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 67.74 on June 18, 2026. This achievement marks a notable recovery from its 52-week low of USD 22.29, showcasing a substantial price movement over the past year. Despite this recent high, Moderna's one-year performance reflects a decline of 56.96%, contrasting sharply with the S&P 500's gain of 25.41% during the same period. The company's market capitalization stands at approximately USD 19,573 million, indicating its mid-cap status within the industry. Financial metrics reveal that Moderna is currently loss-making, with a negative return on equity of -32.62% and a debt-to-equity ratio of -0.60. Additionally, the company does not offer a dividend, and its price-to-book ratio is recorded at 2.26. As Moderna continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this recent price milestone highlights the stock's volatility and the ongoing developments within the company.